Phase three studies were done to compare the safety and efficacy of G versus Cisplatin plus Docetaxel (CD). Patients with stage IIIB/IV or postoperative recurrent EGFR mutation NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.